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HMGCS2 is a key ketogenic enzyme 
potentially involved in type 1 
diabetes with high cardiovascular 
risk
Sanket Kumar Shukla1, Weijing Liu2, Kunal Sikder1, Sankar Addya3, Amrita Sarkar1, Yidong 
Wei4 & Khadija Rafiq1
Diabetes increases the risk of Cardio-vascular disease (CVD). CVD is more prevalent in type 2 
diabetes (T2D) than type 1 diabetes (T1D), but the mortality risk is higher in T1D than in T2D. The 
pathophysiology of CVD in T1D is poorly defined. To learn more about biological pathways that are 
potentially involved in T1D with cardiac dysfunction, we sought to identify differentially expressed 
genes in the T1D heart. Our study used T1D mice with severe hyperglycemia along with significant 
deficits in echocardiographic measurements. Microarray analysis of heart tissue RNA revealed that the 
T1D mice differentially expressed 10 genes compared to control. Using Ingenuity Pathway Analysis 
(IPA), we showed that these genes were significantly involved in ketogenesis, cardiovascular disease, 
apoptosis and other toxicology functions. Of these 10 genes, the 3-Hydroxy-3-Methylglutaryl-CoA 
Synthase 2 (HMGCS2) was the highest upregulated gene in T1D heart. IPA analysis showed that 
HMGCS2 was center to many biological networks and pathways. Our data also suggested that apart 
from heart, the expression of HMGCS2 was also different in kidney and spleen between control and STZ 
treated mice. In conclusion, The HMGCS2 molecule may potentially be involved in T1D induced cardiac 
dysfunction.
Cardiovascular disease (CVD) is one of the most common disease in patients with diabetes. Although the CVD 
is more prevalent in type 2 diabetes (T2D), but the mortality risk is higher in TID than in T2D1, 2. Most published 
work on CVD has been focused on the T2D and assumed that pathogenesis of CVD is similar to that in T1D. 
Despite hyperglycemia representing a common diagnostic phenotype between T1D and T2D, the two diseases 
are far more different3. Therefore, mechanism of CVD can also be different in both type of diabetes. Very little 
information is currently available regarding outcomes of T1D patients following CVD.
Hyperglycemia and metabolic disorder cause oxidative stress, which in turn causes overproduction of reac-
tive oxygen species (ROS) and impaired antioxidant function of tissue. After long term exposure to ROS, tissue 
develops chronic inflammation and fibrosis which leads to cardiac dysfunction4. Numerous experimental studies 
found that cardiac dysfunction is associated with altered cardiac substrate and energy metabolism5, 6. In recent 
years’ investigators have reported that ketone bodies induce oxidative stress and upregulate several signaling 
pathways involved in diabetic complications7, 8. Metabolic and bioenergetics pathway indicate that ketone body 
metabolism could play an important role in the myopathic heart9. However, how ketone bodies affect the diabetic 
heart specifically in T1D is still not known. Moreover, the key molecules involved in this pathway still need to be 
identified.
Thus, in the current study, we performed genome-wide analyses in heart tissue of T1D mice model with car-
diac dysfunction by means of microarray technique to identify novel molecules and pathways. By using Ingenuity 
Pathway Analysis, we have presented a detail bioinformatics analysis of a set of 10 genes selected from microarray 
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data to evaluate the pathways and networks involved during the process of T1D associated CVD. Further, we 
identified hydroxymethylglutaryl (HMG)-CoA synthase 2 (HMGCS2) as the most upregulated gene and a key 
ketogenic enzyme for all biochemical pathways and networks in T1D mice with cardiac dysfunction. We have 
also presented a detailed expression of signaling pathways that could be regulated by HMGCS2 during the devel-
opment of cardiac dysfunction in T1D.
Material and Method
Animals. C57BL/6 male mice, 8 to 10 weeks of age, were purchased from the Jackson Laboratory (Bar Harbor, 
Maine) and housed at Thomas Jefferson University at 22 °C with a 12-h light/dark cycle with free access to standard 
rodent chow and tap water. All animal protocols have been approved by the Institutional Animal Care Committee 
of Thomas Jefferson University, and experiments conformed to the Guide for the Care and Use of Laboratory 
Animals published by the U.S. National Institutes of Health and approved by the American Physiological Society. 
All the methods were carried out in accordance with the relevant guidelines and regulations.
T1D was introduced to the mice by injecting STZ [Sigma-Aldich, St. Louis, MO], dissolved in 0.1 M sodium 
citrate (pH 4.5) at 50 mg/kg body weight, i.p. for 5 consecutive days. While age-matched control mice received 
sodium citrate buffer injection in the same manner. Five days after the last injection of STZ, mice with hypergly-
cemia (blood glucose levels ≥250 mg/dl) were defined as diabetic as described previously10. Mice were sacrificed 
for experimental measurements at 8 weeks after STZ injection.
Hemodynamic and echocardiography measurements. Echocardiographic measurements were done 
before STZ injection as well as at 8 weeks after STZ injection to determine the baseline heart function and ven-
tricular dimensions in the experimental groups. Briefly, following light sedation with 1% isoflurane, the mice were 
placed on a heated platform in the left lateral decubitus position for imaging. A Visualsonic Ultrasound System 
(Vevo770, Toronto, Canada) containing a 40 Mhz variable frequency probe was used to capture the echocardio-
gram. All hair was removed from the chest using a chemical hair remover and the aquasonic clear ultrasound gel 
(Parker Laboratories, Fairfield, NJ) without bubbles was applied to the thorax surface to optimize the visibility of 
the cardiac chambers. Standard long and short axis M-Mode views were recorded when the mouse possessed a 
target heart rate between 450 and 550 beats per minute. Percent fractional shortening was calculated using:
= − × .%FS [(LVEDD LVESD)/LVEDD] 100
LVEF was calculated using the cubed method:
= − .LVEF [(LVEDD) (LVESD) ]/(LVEDD)3 3 3
Microarray analysis. Total LV heart RNA was isolated from STZ-treated WT and age-matched control mice. 
RNA isolation was done using RNeasy mini kit (Quigen, Mansfield, MA), according to manufacturer instruc-
tions. The RNA quality measurement was performed as previously described11. Fragmented biotin labelled cDNA 
(from 100ng of RNA) was synthesized using the GeneChip WT PLUS reagent kit (Affymetrix, Santa Clara, CA). 
The protocols for microarray experiments were previously described12. In brief, Affymetrix gene chips, Mouse 
Gene 2.0 ST Array were hybridized with 4.5 µg fragmented and biotin-labeled cDNA in 200 µl of hybridization 
cocktail. Target denaturation was performed at 99 °C for 5 min and then 45 °C for 5 min, followed by hybridization 
for 16 h at 45°C. Then the arrays were washed and stained using Genechip Fluidic Station 450, using Affymetrix 
GeneChip hybridization wash and stain kit. Chips were scanned on an Affymetrix Gene Chip Scanner 3000 7G, 
using Command Console Software.
Quantitative real-time (qRT-PCR). cDNA was generated from 1–5 µg of total RNA using High Capacity 
RNA-to-cDNA kit (Life Technology Grand Island, NY) according to the manufacturer’s instruction. qRT-PCR 
assays were performed using PerfeCT Super Green Super Mix (Quanta Biosciences, Beverly, MA) by using spe-
cific primers (Invitrogen, Carlsbad, CA) Differences in expression were determined by the relative quantification 
method; the cycle threshold (CT) values of the target genes were first normalized to the CT values of endogenous 
control GAPDH.
Ingenuity Pathway Analysis (IPA). The list of differentially expressed genes was loaded into Ingenuity 
Pathway Analysis (IPA) 8.0 software (http://www.ingenuity.com) to perform biological network and functional 
analyses as reported previously13.
Antibodies. The following antibodies were used for western blot. HMGCS2 antibody was purchased from 
Abcam (Cambridge, MA). pERK(Thr202/Tyr204), pAkt(S473),pP38(pT180/pY182), pJNK(p183/p185) and 
NFkB(p65,D14E12) antibodies were purchased from Cell Signaling Technology, (Danvers, MA). ERK, AKT and 
P38 antibodies were purchased from Santa Cruz Biotechnology (Dallas, Texas).
Ketone bodies measurement. Whole blood was isolated by cardiac puncture in mice model and serum were used 
to measure ketone bodies. The β-hydroxy butyrate (ketone body) level were measured by β-hydroxy butyrate 
calorimetric assay kit (Biovision Incorporated, Milpitas CA) as per manufacturer instruction.
Statistical analysis of microarray data. Data analyses were performed by using GeneSpring software 
version 14.5 (Agilent Technologies, Inc., Santa Clara, CA). A paired t-test compared the “before” and “after” 
treatment samples. A statistical threshold of p < 0.05 with fold-change (FC) ≥ 2 was considered as significant for 
www.nature.com/scientificreports/
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identification of differentially expressed genes. The probe set signals were calculated with the Iterative Plier 16 
summarization algorithm; baseline to median of all samples was used as baseline option.
Results
Characterization of cardiac dysfunction in T1D mice model. T1D was confirmed in mice at 7 days 
after STZ injection based on a blood glucose level > 250 mg/dl. STZ-induced diabetic mice showed severe hyper-
glycemia that correlated with a decrease in body weight and heart weight, resulting in a slight increase of heart to 
body weight (HW/BW) ratio as compared to the non-diabetic control mice (Fig. 1A–D). Given these morpho-
logical findings, we next evaluated the cardiac function of STZ treated mice by echocardiography. Left ventricular 
ejection fraction (LV EF) and LV systolic function (Fractional Shortening; FS) were significantly reduced in the 
diabetic hearts (Fig. 1E,F). STZ treated diabetic mice had significantly increased left ventricular internal dimen-
sion in systole (LVIDs) (Fig. 1H). Although the left ventricular internal dimension in diastole (LVIDd) was higher 
in STZ treated mice but not significantly different from control (Fig. 1G). However, there was significant increase 
in LVIDd/PWD ratio in STZ treated mice compared to control (Fig. 1I).
Figure 1. The morphological and echocardiography measurement in STZ treated mice. (A) Blood Glucose; 
(B) Body weight (BW); (C) Heart weight (HW); (D) HW/BW ratio in control and STZ treated mice. 
Echocardiographic analysis of (E) Ejection Fraction (EF); (F) fractional shortening (FS); (G) left ventricle 
internal diameter, systole (LVIDs); (H) left ventricle internal diameter, diastole (LVIDd); (I) LVIDd/PWD ratio 
in control and STZ treated mice (*P < 0.05).
www.nature.com/scientificreports/
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Gene expression profiling in heart tissues of STZ-induced T1D mice. Gene expression profiling 
was performed using Affymetrix gene chips, Mouse gene 1.0 ST array. By using a 2-fold cut off for changes in 
expression and a P value < 0.05, the chip array revealed that the total of 10 genes were differentially expressed in 
STZ induced T1D mice compared to control (Fig. 2A). These genes were either up- or down- regulated based on 
heat map after cluster algorithms (Fig. 2A).
We surveyed the literature to identify the functional significance of these 10 genes. Details on the function of 
these genes including p-values appear in Table 1. In summary, among the top 10 differentially regulated genes, 
HMGCS2 was most upregulated (5.40 fold). HMGCS2 is a mitochondrial enzyme that catalyzes the first reaction 
of ketogenesis, a metabolic pathway that provides lipid-derived energy during the fasting14. Other genes such as 
ANKRD1 (ankyrin repeat domain 1), PDK4 (Pyruvate dehydrogenase kinase, isoenzyme4), NPPA (Natriuretic 
peptide A) and SERPINE-1 (Serpine peptidase inhibitor) were also found to be upregulated. We also found that 
some genes including ARNTL (aryl hydrocarbon receptor nuclear translocator like), SLC41 A3 (solute carrier 
family 41 member 3), BDH1 (3-hydroxybutyrate dehydrogenase, type 1), CDKN1A (cyclin-dependent kinase 
inhibitor 1A) and MYOT (Myotilin) were significantly downregulated in STZ induced TID.
Next, we confirmed our gene array data and observations by qRT-PCR analysis. We used the same samples 
in each time point as for the microarray analysis. To check the specificity of our microarray data, we performed 
qRT-PCR for all 10 differentially expressed genes. All of the reactions were performed in triplicate from total 
RNA samples from each specimen at each group. We found qRT-PCR expression profiles were highly similar to 
microarray data (Fig. 2B). Figure 2C illustrates the correlation between qRT-PCR and microarray data, with a 
resulting correlation coefficient of r = 0.8171(P < 0.05 at 95% confidence level).
Bioinformatics analysis of the transcriptomic data. To gain insight into how T1D may affect the cel-
lular functions and classes of molecules in cardiac dysfunction, we used the Ingenuity Pathway Analysis (IPA) 
software to perform a comprehensive analysis of the transcriptome variations.
Figure 2. Co-differentially-expressed genes in STZ treated T1D mice with cardiac dysfunction. (A) Heat map 
represents data of all 10 differentially expressed genes in STZ-treated diabetic mice compared with control. 
Genes were identified by performing t tests on the large original dataset and comparing each diabetic group 
with the relative control group. Features with significantly different expression (P < 0.05) were included. The 
heat map is organized with individual samples arranged along the Y-axis, and the relative ratios of expression 
are indicated by color. Color intensity is scaled as highest expression corresponding to bright red and the 
lowest expression corresponding to bright blue. Genes that are up- or down-regulated ≥ 2-fold are displayed 
in red (up-regulation) and blue (down-regulation) respectively. (B) qRT-PCR expression bar diagram of all 10 
differentially expressed genes. (C) Correlation in gene expression between microarray (x-axis) and qRT-PCR 
(y-axis) changes in gene expression with r = 0.8171; *P < 0.05.
www.nature.com/scientificreports/
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Pathway analysis of differentially expressed genes in STZ induced T1D heart. To further explore the differences 
between expressions of genes in T1D associated CVD, we compared the genes that were differentially expressed 
in the hearts of mice with STZ-induced T1D. The differentially expressed genes were more likely to belong to 
ketogenesis, glucocorticoid receptor, ketolysis and mevalonate pathways (Fig. 3).
Functional annotation of genes differentially regulated in STZ-induced T1D heart. The IPA comprised 2 struc-
tured networks: (1) disease and bio functions and (2) toxicity functions. The data was calculated based on the 
percentage of molecules which were significantly associated with all the functions. Through IPA analysis, we 
found that the differentially expressed mRNAs were principally enriched for various disease functions such as 
organismal injury, cancer, endocrine, cardiovascular disease as well as renal and urological disorders (Fig. 4A). 
The dysregulated genes were also associated with molecular and cellular functions such as cell death and survival, 
lipid and amino acid metabolism and cell morphology (Fig. 4B). The top physiological and development func-
tions were tissue morphology, connective tissue, skeleton, urological and hematological development and func-
tion (Fig. 4C). We also analyzed the toxicology functions all differentially expressed genes and found these genes 
were involved in major organ specific toxicology functions such as cardiotoxicity, hepatotoxicity and nephrotox-
icity functions (Fig. 4D–F).
Molecular Networks map generated by the Ingenuity Pathway Analysis tool. To examine the interaction of the 
differentially regulated genes with other gene products, we formed molecular networks in IPA using functional 
relationships. The molecular networks between gene products, based on known connections in peer-reviewed 
literature, revealed the molecules involved in different pathways, binding, activation, inhibition and biological 
process during T1D associated CVD.
Gene Gene Product
Fold 
Change P value Function
Up-regulated
HMGCS2 3-hydroxy-3-methylglutaryl-CoenzymeA synthase2 5.40 0.003 Ketogenesis
ANKRD1 Ankyrin repeat domain 1 2.12 0.007 Regulate myofibrillar stretch-sensor system
PDK4 Pyruvate dehydrogenase kinase, isoenzyme4 2.10 0.02 Inhibits conversion of pyruvate to acetyl CoA
NPPA Natriuretic peptide A 2.05 0.02 Electrolyte homeostasis
SERPINE1 Serpin peptidase inhibitor 2.03 0.01 Serine proteinase inhibitor (serpin) superfamily
Down-regulated
ARNTL Aryl hydrocarbon receptor nuclear translocator like 2.89 0.03 Circadian clock
SLC41A3 Solute Carrier family 41 member 3 2.58 0.0007 Transmembrane Transport
BDH1 3-hydroxybutyrate dehydrogenase, type 1 2.53 0.04 Mitochondrial membrane enzyme
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 2.12 0.01 Regulator of cell cycle progression at G1
MYOT Myotilin 2.10 0.03 Stability of thin filaments during muscle contraction
Table 1. Function of top 10 genes up- or down-regulated in T1D associated with CVD.
Figure 3. IPA canonical pathway analysis of differentially expressed genes in STZ-treated T1D mice with 
cardiac dysfunction. The bar diagram represents the top 5 over-represented canonical pathways in T1D 
associated with CVD. Category names are presented on the y-axis. The x-axis indicates the p value of the over-
representation analysis. The inclusion of pathways is based on the presence of any 10 differentially regulated 
genes in DCM.
www.nature.com/scientificreports/
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All of the 10 differentially expressed genes were used in the IPA network analysis. Two main networks were 
identified. The top network with an IPA scores of 17 and includes genes and pathways involved in Amino Acid 
Metabolism, Small Molecule Biochemistry and Cellular Development (Fig. 5A). This network clearly showed that 
most of the differentially expressed genes are involved and regulated by different signaling pathways such and 
PI3K/AKT, MAPK/ERK and NFkB. Other top networks, with an IPA score of 7, include Cellular Development, 
Hematological System Development and Function, Hematopoiesis (Fig. S1).
We also performed upstream regulator analysis by IPA. This tool predicts which upstream regulators are acti-
vated based on our microarray expression data. Our data predict increased activation for upstream regulators 
AKT, DYRK1A, ZFYVE16, INSR and mir-30 (P < 0.05) contributed to T1D with cardiac dysfunction.
To explore the underlying signaling mechanisms for the above process we conducted a throughput analysis 
of several pathways that were present in IPA network. Figure 5B shows that after diabetes induction, AKT and 
ERK phosphorylation were decreased as compare to control. However, P38 phosphorylation was increased. These 
effects are critical for regulation of cadiac growth and survival. It is noteworthy, that the increase or decrease in 
AKT, ERK or P38 phosphorylation was not associated with an increase or decrease at the expression levels of 
these molecules at this stage of diabetes. We also found the down regulation of NFkB pathway in STZ treated 
diabetic mice (Figure 5B).
Differential expression of HMGCS2 gene in various organs of T1D mice. In the current study, the 
most up-regulated gene HMGCS2 was 5.2-fold increased at the mRNA level. This increase was surprising since 
Figure 4. Top functions of over expressed genes in STZ treated T1D mice with cardiac dysfunction. (A) Top 
disease and disorders, (B) Top molecular and cellular function, (C) Top physiological system and development 
and function, (D–F) Organ-specific top toxicology function. The X axis represents the percentage of molecules 
among 10 differentially expressed genes involved in different functions.
www.nature.com/scientificreports/
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the HMGCS2 enzyme is typically present in the heart at early stages of perinatal development15. This molecule is 
generally involved in ketogenesis in the liver when high fatty acids are available16. Therefore, our next experiments 
were designed to determine whether HMGCS2 expression was increased by diabetes only in the heart or other 
vital organs such as the liver, kidney and spleen. The expression of HMGCS2 was checked both at mRNA and 
protein level by qRT-PCR and western blot respectively. The expression of HMGCS2 (both mRNA and protein 
levels) was significantly higher in heart, kidney and spleen tissue of T1D mice compared to control. A higher basal 
expression of HMGCS2 was detected in liver compared to other organs but no significant difference was observed 
in STZ treated mice compared to control (Fig. 6). Our next experiment was designed to determine whether 
HMGCS2 overexpression might correlated with ketone body synthesis. We measured β-hydroxy butyrate level 
in serum sample of mice model. An elevated level of β-hydroxy butyrate level was reported in T1D compared to 
control (Fig. S2). This result supports that HMGCS2 is a key molecule in T1D which is involved in ketone body 
synthesis.
Discussion
The mechanisms responsible for T1D associated cardiac dysfunction are complex and poorly understood17. A 
previous concept has linked oxidative stress, inflammation and apoptosis to the maladaptive cardiac structural 
and functional consequences of diabetes associated cardiac dysfunction18, 19. Chronic hyperglycemia, induced 
by STZ, may prompt a cascade of complex pathophysiological events characterized by biochemical and func-
tional myocardial abnormalities in mice, eventually leading to heart failure20. To define molecular mechanism, 
it is important to identify novel molecules and pathways for novel therapeutic approaches during the process of 
cardiac dysfunction in T1D.
Our most remarkable finding from our microarray analyses was that we identified differentially expressed 
genes associated with cardiac dysfunction in T1D. Among all 10 differentially expressed genes, HMGCS2 was the 
most upregulated gene. This enzyme is generally known to be involved in ketone synthesis pathways21. Although 
few studies have reported the expression of HMGCS2 in the heart tissue22, 23 none have investigated its role inT1D 
during the development of cardiac dysfunction. More recently Cook et al.24 reported that expression of HMGCS2 
was higher in T1D rat24. However, this study did not adequately explore the cardiac dysfunction and pathway 
analysis for HMGCS2 during the development of T1D. To the best of our knowledge our study is the first to 
report that upregulation of HMGCS2 is associated with STZ induced T1D mice that lead to cardiac dysfunction. 
Moreover, with the IPA analysis we also explored the network and pathway analysis of HMGCS2 and other dif-
ferentially expressed genes in T1D associated cardiac dysfunction for the first time. In agreement with previous 
studies25–27, we found that PDK4, NPPA, ANKRD and SERPINE1 were upregulated in our model and may con-
tribute to cardiac dysfunction in T1D.
We also analyzed down-regulated genes in T1D-associated cardiac dysfunction. Interestingly, Solute Carrier 
family 41 member 3 (SLC41 A3) was the most significantly down-regulated gene in our study. SLC41 A3 is a 
recently discovered transmembrane protein that regulates dietary Mg2+ intake28. However, the role of SLC41A3 
in T1D associated with cardiac dysfunction are unknown and needs to be identified.
Figure 5. Functional gene networks identified using IPA for STZ-induced T1D with cardiac dysfunction. 
(A) Representative diagram of top network identified named as Amino acid Metabolism, Small Molecule 
Biochemistry, Cellular Development (IPA score 17). Nodes represent genes, whereas shapes represent a 
functional class of gene product. Intensity of the node color indicates the degree of overexpression (red) and 
the degree of down-regulation (green). Genes in uncolored nodes were not identified as differentially expressed 
and were integrated into computationally generated networks based on information in the IPA database. The 
network diagram was generated by Ingenuity® Pathway Analysis software (QIAGEN, Bioinformatics, Redwood 
City, CA), www.qiagenbioinformatics.com. (B) Differential expression profile of MAPKs and NFkB in heart 
tissue of the control and STZ treated mice.
www.nature.com/scientificreports/
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We performed pathway analysis of all of differentially-expressed genes using the IPA software. The top path-
ways involved with these genes included ketogensis, ketolysis, glucocorticoid receptor signaling and mevalonate 
pathway. Ketogenesis is the common phenomenon in T1D diabetic patients who are not able to make insulin7. 
T1D disrupts the balance between ketogenesis and ketolysis, which results in a high ketone level called hyper-
ketonemia29. Previous studies also found that these ketone bodies induce oxidative stress which may affect the 
biological and cellular functions7, 27, 30. However, it is still unclear how ketones behave in a cardiac dysfunction 
with hyperglycemic state. Our data suggest that the T1D triggers expression of many genes that are potentially 
involved in the ketone body synthesis pathway in the diabetic heart. Therefore, there is a need to reassess the role 
of ketone bodies synthesis in T1D associated with cardiac dysfunction. There is also need to re-evaluate each mol-
ecule that is differentially expressed in our current study to learn how they are involved in ketogenesis pathway.
Based on the 10 differentially expressed genes, we performed a network analysis and defined a network related 
to ‘amino acid metabolism, small molecule biochemistry and cellular development’ within which six of the 10 
characterized genes were placed. This network centers on SERPINE1, a serine protease inhibitor that acts as 
bait for tissue plasminogen activator and that has also been shown to be associated with diabetes31. This net-
work also revealed several other interesting regulatory proteins, especially the aryl hydrocarbon receptor nuclear 
translocator-like protein (ARNTL), which serve as a transcription regulator and is involved in circadian func-
tion32. ARNTL has also been associated with hypertension, diabetes, and obesity32. Activation of the ARNTL 
could prevent diabetes by increasing Foxp3+ regulatory T cells. Our network analysis showed that ARNTL is 
regulated by different kinase pathways and directly linked with HMGCS2. Previously, Oishi et al.33 found that 
circadian clock gene expression is disrupted in peripheral tissues of hypothermic mice fed a ketogenic diet33. 
Therefore, it could be possible that ARNTL may act as transcriptional regulator for HMGCS2 and involved in 
ketogenesis pathways during the development of T1D associated CVD. However, this statement calls for further 
study.
Our study also reported the differential expression of several signaling molecule. Many recent studies have 
shown that ketone bodies induce oxidative stress and upregulate several signaling pathways including ERK1/2, 
p38MAP, NFkB and Akt7, 34. These signaling molecules enhance adhesion molecule expression which results in 
leukocyte infiltration that leads to tissue damage7.
HMGCS2 is generally expressed in liver where it converts acetyl-CoA to ketone bodies35. Although the expres-
sion of HMGCS2 was detected in extra-hepatic organs, its role is undefined36, 37. We found overexpression of 
HMGCS2 in T1D mice heart tissue with cardiac dysfunction. To explore whether HMGCS2 expression is organ 
specific or other vital organs also differentially express HMGCS2, we checked the expression of HMGCS2 in 
heart, liver, kidney and spleen. Our data showed that the expression of HMGCS2 was differentially expressed at 
Figure 6. Expression profile of HMGCS2 in different tissues of STZ treated T1D mice with cardiac dysfunction. 
(A) The expression profile of HMGCS2 at mRNA level by real-Time PCR in heart, liver, kidney and spleen. (B) 
The expression profile of HMGCS2 at protein level by western blot in heart, liver, kidney and spleen.
www.nature.com/scientificreports/
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both the mRNA and protein level in T1D mice heart tissue. This data confirms our microarray results. Kidney and 
heart maintain a metabolic response that controls ketone body utilization36, 37. Different experimental approaches 
have established that cardiac dysfunction is related to changes in cardiac energy metabolism38–40. Therefore, it 
could be possible that HMGCS2 plays a role in cardiac energy metabolism during the cardiac dysfunction related 
to T1D. However, this hypothesis warrants future study. Although the expression of HMGCS2 was higher in liver 
but the expression was not different among control and T1D mice. In concordance with our findings, a previous 
study also did not identify any significant difference of HMGCS2 with diabetic states24. We also found that, apart 
from heart, the expression of HMGCS2 was also significantly elevated in the kidney and spleen. A study found 
that HMGCS2 expression was abundant in renal glomeruli of diabetic mice. This result further suggested that 
upregulation of HMGCS2 increased renal ketogenesis which ultimately leads to the diabetic nephropathy that 
occurs in type 2 diabetes36. A literature search did not identify any report where HMGCS2 expression was stud-
ied in spleen. We therefore are the first to report that T1D leads to an increase of HMGCS2 expression in spleen 
tissue.
In conclusion, the present study determined the global expression profile of genes in T1D associated with 
cardiac dysfunction and conferred their physiological significance. T1D-associated CVD induced a cohort of 
mRNAs that is associated mainly with ketogenesis and ketolysis pathways. HMGCS2, a ketogenic enzyme was 
the most up-regulated gene in T1D heart tissue. This result was unanticipated because until now, no such studies 
have ever reported ketone body synthesis in the diabetic heart. Further studies are required to investigate the 
molecular mechanisms involved in the up-regulation of HMGCS2 expression in diabetic heart tissue. The ketone 
body also needs to be assessed during the development of T1D-related cardiac dysfunction.
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